이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

TELA Bio 관리

관리 기준 확인 2/4

TELA Bio's CEO는 Antony Koblish, Apr2012 에 임명되었습니다 의 임기는 12.17 년입니다. 총 연간 보상은 $ 2.37M, 25.2% 로 구성됩니다. 25.2% 급여 및 74.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.08M 가치에 해당하는 회사 주식의 0.87% 직접 소유합니다. 1.08M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 4.6 년입니다.

주요 정보

Antony Koblish

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	25.2%
CEO 임기	12.2yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29

Recent updates

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates

Mar 30

Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?

Feb 12

TELA Bio guides Q4 and FY20 revenue below consensus

Jan 14

TELA Bio EPS misses by $0.09, beats on revenue

Nov 11

CEO 보상 분석

Antony Koblish 의 보수는 TELA Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$2m	US$595k	-US$47m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$566k	-US$44m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$2m	US$538k	-US$33m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$806k	US$479k	-US$29m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	US$2m	US$403k	-US$30m
Sep 30 2019	n/a	n/a	-US$32m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$569k	US$375k	-US$30m

보상 대 시장: Antony 의 총 보상 ($USD 2.37M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Antony 의 보상이 증가했습니다.

CEO

Antony Koblish (58 yo)

12.2yrs

테뉴어

US$2,366,371

보상

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...

리더십 팀

이름	위치	테뉴어	보상	소유권
Antony Koblish	Co-founder	12.2yrs	US$2.37m	0.87% $ 1.1m
Roberto Cuca	CFO & COO	2.8yrs	US$1.06m	0.16% $ 201.4k
Paul Talmo	Chief Technology Officer	no data	US$962.24k	0.12% $ 151.8k
Megan Smeykal	VP, Corporate Controller	3.1yrs	데이터 없음	0.033% $ 41.3k
D. Ocasio	General Counsel & Corporate Secretary	2.2yrs	데이터 없음	데이터 없음
Jennifer Armstrong	Senior Vice President of Human Resources	2.4yrs	데이터 없음	데이터 없음
Gregory Firestone	Chief Commercial Officer	no data	데이터 없음	0.21% $ 257.2k
Michael Leonard	Senior Vice President of Technical Operations	2.4yrs	데이터 없음	데이터 없음
Peter Murphy	Chief Commercial Officer	4.4yrs	US$936.76k	0.055% $ 68.8k
Louisa Smith	Investor Relations Contact Officer	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: TELA 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Antony Koblish	Co-founder	12.2yrs	US$2.37m	0.87% $ 1.1m
Vincent Burgess	Independent Director	11.5yrs	US$128.59k	0.045% $ 56.5k
Federica O'Brien	Independent Director	4.6yrs	US$133.59k	0.025% $ 31.9k
Douglas Evans	Independent Chairman of the Board	4.2yrs	US$161.09k	0.025% $ 31.9k
Lisa Colleran	Independent Director	4.2yrs	US$133.59k	0.025% $ 31.9k
Kurt Azarbarzin	Independent Director	5.6yrs	US$121.09k	0.025% $ 31.9k
Jeffrey Blizard	Director	no data	데이터 없음	데이터 없음

4.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: TELA 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

TELA Bio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

Insufficient new directors

Recent updates

TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer

TELA Bio, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)

TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX

Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Consensus EPS estimates fall by 215%

TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 18% to US$14.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Consensus EPS estimates upgraded to US$0.57 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations

TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Insufficient new directors

Consensus EPS estimates fall by 13%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack

Price target decreased to US$17.40

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.40

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022

TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Consensus forecasts updated

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million.

Tela Bio prices $32M common stock offering

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs

TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

TELA Bio - Follow Up With Management

High number of new directors

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020)

Our First Look At TELA Bio

TELA Bio Plugging Away

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020)

TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021

High number of new directors

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index

Independent Director Adele Oliva has left the company

Chief Financial Officer Nora Brennan has left the company

TELA Bio (TELA) Investor Presentation - Slideshow

TELA Bio, Inc. Initiates Bravo II Study of Ovitex for the Robotic Repair of Ventral Hernias